Allogeneic Donor Derived Lmp Specific Cytotoxic T-Lymphocyte
Leiomyosarcoma
Explore 18 assets in Leiomyosarcoma →Floatz Rating
C32/100
Confidence
Indicative
Sponsor
Baylor College of Medicine
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
17Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01447056CT.gov Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Leiomyosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allogeneic Donor Derived Lmp Specific Cytotoxic T-Lymphocyte (this asset) | Baylor College of Medicine | P1 | C · 32 |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Temsirolimus | National Cancer Institute (NCI) | P2 | B |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
| Berzosertib | Massachusetts General Hospital | P2 | B |
| Olaparib | University Health Network, Toronto | P2 | CCC |
| Tabelecleucel | Pierre Fabre Medicament | P2 | CCC |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | CCC |
| Durvalumab | University Health Network, Toronto | P2 | CCC |
+18 more in the Leiomyosarcoma cohort
Other indications for Allogeneic Donor Derived Lmp Specific Cytotoxic T-Lymphocyte
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P2 | CC · 40 |
| Lymphoproliferative Syndrome | — | P1 | C · 32 |
| Nasopharyngeal Carcinoma | — | P1 | C · 32 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allogeneic Donor Derived Lmp Specific Cytotoxic T-Lymphocyte in Leiomyosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allogeneic-donor-derived-lmp-specific-cytotoxic-t-lymphocyte-leiomyosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →